Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: PFE US EQUITY

Pfizer Inc (New York: PFE, Currency: USD)

Sector: Salud   Industry: Productos farmacéuticos   Sub-Industry: Productos farmacéuticos

Website	www.pfizer.com
Number of Employees	81,000
Ticker:	PFE US

66 Hudson Blvd East New York, NY 10001 United States
Phone : 1-212-733-2323
Fax : 1-212-573-7851

26.25 +0.31 #¡VALOR!

Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

-- --   -- -   --   **FECHA:**   **06/03/2025**

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	26.33	**Market Cap (MM)**	149,192.7
Open	25.93	**Shares Out. (MM)**	5,667.3
Previous Close	25.94	**Float %**	99.2%
Change	0.19	**Shares sold short (MM)**	89,117,210.0
Change %	0.74	**Dividend Yield %**	6.4
Day High/Day Low	26.5 / 25.9	**Diluted EPS Excl. XO**	
52 Wk High/52 Wk low	31.5 / 24.5	**P / Diluted EPS Before XO**	
Volume (MM)	27.42	**Beta**	0.44
Avg. Vol - 3 mo (MM)	40.35		

Financial Information (Currency: USD, in mm)

Revenue - LTM	63,627.0	**Cash & ST Invst.**	20,477
EBIT - LTM	12,411.0	**Total Assets**	213,396.0
EBITDA - LTM	19,424.0	**Total Debt**	66,993.0
Net Income - LTM	8,031.0	**Total Liabilities**	124,899.0
Total Enterprise Value	196,003	**Total Equity**	88,497.0
TEV/ Total Revenue	3.1 x	**Cash from Operations - LTM**	12,744.0
TEV/ EBITDA	10.2 x	**Cash From Investing - LTM**	2,652.0
		Cash from Financing -LTM	-17,206.0

Company Notes

2015 Q3
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $470.000 from Asset Write Down
A loss of $529.000 from Restructuring
A loss of $163.000 from Impairment of Intangibles
A loss of $124.000 from Merger & Acquisition.
A gain of $35.000 from Disposal of assets.
A loss of 92.000 from various one time items.

2015 Q2
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $304.000 from Other One Time Items
A loss of $25.000 from Asset Write Down
A loss of $68.000 from Merger/Acquisition Expense
A gain of$ 5.000 from Investments, a gain from $ 15.000 from disposal of asset, A loss of $25.000 from impairment of asset
.

2015 Q1
GAAP Net Income includes, (in millions, after-tax):
a loss of $17.000 from Acquisition/Merger
a loss of $167.000 from Various One-Time Items
a gain of $5.000 from Discontinued Operations

2014 A1
GAAP Net Income includes, (in millions):
a pre-tax gain of $288.000 from Disposal of Assets
a pre-tax loss of $1,630.000 from Impairment/Legal
a pre-tax loss of $250.000 from Restructuring/Acquisition
an after-tax gain of $48.000 from Discontinued Operations

2014 Q1
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $140 from Restructuring
A loss of $694 from Legal Expense
A loss of $139 from Impairments and M & A Expense
A gain of $210 from Asset Disposal, Derivatives, and other

2013 A1
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $1431 from Restructuring, A gain of $1321 from Legal Expense, A loss of $144 from M & A Expense, A gain of $38 from Derivatives,A loss of $1224from Impairments,A gain of $125 from Asset Disposal, A gain of $195 from Sale of Investment
A gain of $10,623.000 from Discontinued Operations

2013 Q4
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $708 from Restructuring, A loss of $120 from Legal Expense, A loss of $34 from M & A Expense,A gain of $5 from Derivatives, A loss of $176 from Impairments,A gain of $125 from Assets Disposal,A gain of $95 from Sale of Investment
a loss of $58.000 from Discontinued Operations

2013 Q3
GAAP Net Income includes, (in millions, after-tax):
a loss of $54.000 from Acquisition/Merger
a loss of $1,223.000 from Various One-Time Items
a gain of $11.000 from Discontinued Operations

Key Board Members

	Name	Title	Organization
1	Ronald E Blaylock "Ron"	Founder	Blaylock & Partners Lp
2		Partner/Founder	Gennx360 Capital Partners
3		Board Member	Pfizer Inc
4		Board Member	Carmax Inc
5		Board Member	Wr Berkley Corp
6		Board Member	Mebane Charitable Foundation I
7	Susan Desmond-Hellmann "Sue"	Board Member	Openai Inc
8		Board Member	Pfizer Inc
9		Board Member	National Resilience Inc
#		Board Member	Pfizer Venture Investments
#	Suzanne Nora Johnson	Co-Chairman	Brookings Institution/The
#		Chairman	Intuit Inc
#		Board Member	Pfizer Inc
#		Trustee	University Of Southern Califor
#		Chairman	John & Mary R Markle Foundatio
#		Trustee	Carnegie Institution Of Washin
#		Trustee	University Of Southern Califor
#		Board Member	Women'S World Banking Inc
#		Board Member	Technoserve Inc
#		Board Member	Council For Excellence In Govt
#		Board Member	Children Now Inc
#		Board Member	American Red Cross
#		Board Member	Visa Intl Inc
#	Shantanu Narayen	Co-Founder	Pictra Inc
#		Vice Chairman	Us-India Strategic Partnership
#		Chairman/President/Ceo	Adobe Ventures Lp
#		Chair/Ceo	Adobe Inc
#		Lead Director	Pfizer Inc
#		Chairman	Adobe Foundation

Bloomberg

Company In Depth Fundamentals - Key Stats

Ticker:	PFE US EQUITY
Period Type	Annuals

Pfizer Inc

Sector: Salud **Industry:** Productos farmacéuticos **Sub-Industry:** Productos farmacéuticos

Annuals

FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0fs	1FY	2FY	3FY

Key Financials

	Actuals							LTM	Estimates		
For the Fiscal Period Ending	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024	31/12/2024	31/12/2025	31/12/2026	31/12/2027
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Total Revenue	53,647.0	40,905.0	41,651.0	81,288.0	100,330.0	59,554.0	63,627.0	46,928.0	63,627.0	14,493.8	14,493.8
Growth Over Prior Year	*2.1%*	*(23.8%)*	*1.8%*	*95.2%*	*23.4%*	*(40.6%)*	*6.8%*	--	*(2.6%)*	*(2.6%)*	*(2.6%)*
Gross Profit	42,399.0	32,851.0	33,167.0	50,467.0	65,986.0	34,600.0	45,776.0	--	--	--	
Margin %	*79.0%*	*80.3%*	*79.6%*	*62.1%*	*65.8%*	*58.1%*	*71.9%*	--	--	--	--
EBITDA	20,385.0	20,948.0	13,329.0	25,131.0	40,690.0	8,409.0	20,084.0	--	8,792.5	8,792.5	8,792.5
Margin %	*38.0%*	*51.2%*	*32.0%*	*30.9%*	*40.6%*	*14.1%*	*31.6%*	--	*13.8%*	*60.7%*	*60.7%*
EBIT	14,001.0	14,817.0	8,256.0	19,433.0	34,944.0	1,280.0	12,411.0	--	5,066.6	5,066.6	5,066.6
Margin %	*26.1%*	*36.2%*	*19.8%*	*23.9%*	*34.8%*	*2.1%*	*19.5%*	--	*8.0%*	*35.0%*	*35.0%*
Earnings from Cont. Ops.	11,179.0	10,738.0	6,666.0	22,459.0	31,401.0	2,173.0	8,051.0	--	--	--	--
Margin %	*20.8%*	*26.3%*	*16.0%*	*27.6%*	*31.3%*	*3.6%*	*12.7%*	--	--	--	--
Net Income	11,153.0	16,026.0	9,159.0	21,979.0	31,372.0	2,119.0	8,031.0	--	4,060.2	4,060.2	4,060.2
Margin %	*20.8%*	*39.2%*	*22.0%*	*27.0%*	*31.3%*	*3.6%*	*12.6%*	--	*6.4%*	*28.0%*	*28.0%*
Diluted EPS Excl. Extra Items	1.9	1.9	1.2	3.9	5.5	0.4	1.4	--	0.7	0.7	0.7
Growth Over Prior Year	*(47.2%)*	*1.6%*	*(37.6%)*	*233.1%*	*39.2%*	*(93.2%)*	*281.1%*	--	*(13.7%)*	*(13.7%)*	*(13.7%)*

Current Capitalization (Millions)

Currency	USD
Share Price (USD)	26.33
Shares Out.	5,667.34
Market Capitalization (USD)	149,192.74
- Cash & Short Term Investments	0.00
+ Total Debt	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	196,002.74
Book Value of Common Equity	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	0.00
= Total Capital	0.00



PE Ratio

Valuation Multiples based on Current Capitalization

	Actual	LTM	Estimates		
For the Fiscal Period Ending	31/12/2024	31/12/2024	31/12/2024	31/12/2024	31/12/2024
TEV/Total Revenue	3.1x	--	--	--	--
TEV/EBITDA	9.8x	--	--	--	--
TEV/EBIT	15.7x	--	--	--	--
P/Diluted EPS Before Extra	18.8x	--			
P/BV	1.7x	--	--	--	--
Price/Tang BV	--	--			

Valuation Multiples for Chart

For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	11.4x	8.9x	8.9x	8.9x
TEV / EBITDA	10.2x	0.0x	0.0x	0.0x
Price / CF	11.7x	0.0x	0.0x	0.0x
Price / Book	1.7x	0.0x	0.0x	0.0x
Dividend Yield	6.4x	6.4x	6.4x	6.4x



Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**	**31/12/2024**
Currency	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***
Revenue	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	91,793.00	51,972.00	55,239.00
Other Revenue	-	-	-	-	-	-	-	-	8,537.00	7,582.00	8,388.00
Total Revenue	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,651.00**	**81,288.00**	**100,330.00**	**59,554.00**	**63,627.00**
Cost Of Goods Sold	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,484.00	30,821.00	34,344.00	24,954.00	17,851.00
Gross Profit	**40,028.00**	**39,203.00**	**40,495.00**	**41,318.00**	**42,399.00**	**32,851.00**	**33,167.00**	**50,467.00**	**65,986.00**	**34,600.00**	**45,776.00**
Selling General & Admin Exp.	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,170.00	16,974.00	16,005.00	22,641.00	22,543.00
R & D Exp.	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,393.00	10,360.00	11,428.00	10,679.00	10,822.00
Depreciation & Amort.	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,348.00	3,700.00	3,609.00	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	**26,779.00**	**27,379.00**	**28,489.00**	**27,596.00**	**28,398.00**	**18,034.00**	**24,911.00**	**31,034.00**	**31,042.00**	**33,320.00**	**33,365.00**
Operating Income	**13,249.00**	**11,824.00**	**12,006.00**	**13,722.00**	**14,001.00**	**14,817.00**	**8,256.00**	**19,433.00**	**34,944.00**	**1,280.00**	**12,411.00**
Interest Expense	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00	1,238.00	2,209.00	3,091.00
Interest Income	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00	251.00	1,624.00	545.00
Net Interest Exp.	**935.00**	**728.00**	**716.00**	**879.00**	**983.00**	**1,348.00**	**1,376.00**	**1,255.00**	**987.00**	**585.00**	**2,546.00**
Currency Exchange Gains (Loss)	-	806.00	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(156.00)	(6,133.00)	(772.00)	(363.00)	1,842.00
EBT Excl. Unusual Items	**12,240.00**	**8,965.00**	**8,351.00**	**12,305.00**	**11,885.00**	**11,321.00**	**7,036.00**	**24,311.00**	**34,729.00**	**1,058.00**	**8,023.00**
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	**12,240.00**	**8,965.00**	**8,351.00**	**12,305.00**	**11,885.00**	**11,321.00**	**7,036.00**	**24,311.00**	**34,729.00**	**1,058.00**	**8,023.00**
Income Tax Expense	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	370.00	1,852.00	3,328.00	(1,115.00)	(28.00)
Earnings from Cont. Ops.	**9,120.00**	**6,975.00**	**7,228.00**	**21,353.00**	**11,179.00**	**10,738.00**	**6,666.00**	**22,459.00**	**31,401.00**	**2,173.00**	**8,051.00**
Extraord. Item & Account. Change	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,529.00)	434.00	(6.00)	15.00	(11.00)
Minority Int. in Earnings	33.00	26.00	31.00	47.00	36.00	30.00	36.00	46.00	35.00	39.00	31.00
Net Income	**9,135.00**	**6,960.00**	**7,215.00**	**21,308.00**	**11,153.00**	**16,026.00**	**9,159.00**	**21,979.00**	**31,372.00**	**2,119.00**	**8,031.00**
Pref. Dividends	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	**9,133.00**	**6,958.00**	**7,213.00**	**21,307.00**	**11,152.00**	**16,026.00**	**9,159.00**	**21,979.00**	**31,372.00**	**2,119.00**	**8,031.00**
Abnormal Losses (Gains)	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	4,947.00	2,496.00	5,299.00	6,137.00	6,664.00
Tax Effect on Abnormal Items	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(949.34)	(1,406.35)	(1,129.06)	(1,266.11)	(1,587.07)
NI to Common Excl. Extra Items	**11,484.70**	**10,447.85**	**12,925.85**	**12,464.46**	**13,531.33**	**12,421.11**	**13,156.66**	**23,068.65**	**35,541.94**	**6,989.89**	**13,107.93**
Per Share Items											
Basic EPS	1.44	1.13	1.18	3.57	1.90	2.88	1.65	3.92	5.59	0.38	1.42
Basic EPS Excl. Extra Items	1.43	1.13	1.18	3.57	1.90	1.92	1.19	4.00	5.59	0.38	1.42
Weighted Avg. Basic Shares Out.	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00	5,608.00	5,643.00	5,664.00
Diluted EPS	1.42	1.11	1.17	3.52	1.87	2.82	1.63	3.85	5.47	0.37	1.41
Diluted EPS Excl. Extra Items	1.41	1.11	1.17	3.52	1.86	1.89	1.18	3.93	5.47	0.37	1.41
Weighted Avg. Diluted Shares Out.	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00	5,733.00	5,709.00	5,700.00
Normalized Basic EPS	2.26	2.20	2.40	2.65	3.00	2.95	2.22	4.42	6.58	1.85	3.12
Normalized Diluted EPS	1.78	1.67	2.10	2.06	2.26	1.25	1.89	4.12	6.20	1.22	2.30
Dividends per Share											
Payout Ratio %	72.65	99.57	101.55	36.43	72.73	75.93	128.19	39.33	28.81	436.55	119.41
Supplemental Items											
EBITA	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,996.00	23,640.00	39,235.00	6,852.00	18,357.00
EBIT	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,256.00	19,433.00	34,944.00	1,280.00	12,411.00
As Reported Total Revenue*	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	100,330.00	59,554.00	63,627.00
Effective Tax Rate %	25.49	22.20	13.45	-	5.94	5.15	5.26	7.62	9.58	-	-
Normalized Net Income	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,627.66	23,502.65	35,535.94	7,004.89	13,096.93
Interest Capitalized	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00	124.00	160.00	182.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	586.00	669.00	691.00	840.00	949.00	687.00	755.00	1,182.00	872.00	525.00	877.00
Stock-Based Comp., Total	**586.00**	**669.00**	**691.00**	**840.00**	**949.00**	**687.00**	**755.00**	**1,182.00**	**872.00**	**525.00**	**877.00**

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**	**31/12/2024**
Currency	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**
ASSETS											
Cash And Equivalents	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,786.00	1,944.00	416.00	2,853.00	1,043.00
Short Term Investments	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00	22,316.00	9,837.00	19,434.00
Total Cash & ST Investments	**36,122.00**	**23,290.00**	**17,850.00**	**19,992.00**	**18,833.00**	**9,646.00**	**12,223.00**	**31,069.00**	**22,732.00**	**12,690.00**	**20,477.00**
Accounts & Notes Receivable	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,913.00	11,479.00	10,952.00	11,177.00	11,463.00
Total Receivables	**8,401.00**	**8,176.00**	**8,225.00**	**8,221.00**	**8,025.00**	**6,772.00**	**7,913.00**	**11,479.00**	**10,952.00**	**11,177.00**	**11,463.00**
Inventories	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,019.00	9,059.00	8,981.00	10,190.00	10,851.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,912.00	8,086.00	8,594.00	9,276.00	7,567.00
Total Current Assets	**55,595.00**	**43,804.00**	**38,949.00**	**41,141.00**	**49,926.00**	**32,803.00**	**35,067.00**	**59,693.00**	**51,259.00**	**43,333.00**	**50,358.00**
Net Property, Plant & Equipment	**11,760.00**	**13,766.00**	**13,318.00**	**13,865.00**	**13,385.00**	**14,257.00**	**15,131.00**	**17,721.00**	**19,275.00**	**21,865.00**	**20,682.00**
Long-term Investments	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00	15,069.00	15,368.00	2,227.00
Deferred Charges, LT	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00	6,693.00	3,706.00	8,662.00
Other Long-Term Assets	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,386.00	79,195.00	104,909.00	142,229.00	131,467.00
Total Assets	**167,566.00**	**167,381.00**	**171,615.00**	**171,797.00**	**159,422.00**	**167,594.00**	**154,229.00**	**181,476.00**	**197,205.00**	**226,501.00**	**213,396.00**
LIABILITIES											
Accrued Exp.	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,049.00	3,332.00	3,407.00	2,776.00	3,838.00
Short-term Borrowings	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,023.00	2,690.00	3,565.00	10,877.00	7,302.00
Accounts Payable	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,283.00	5,578.00	6,809.00	6,710.00	5,633.00
Curr. Income Taxes Payable	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00	1,587.00	2,349.00	2,910.00
Other Current Liabilities	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,583.00	14,516.00	29,806.00	26,770.00	25,082.00	23,312.00
Total Current Liabilities	**21,587.00**	**29,398.00**	**31,115.00**	**30,427.00**	**31,858.00**	**37,304.00**	**25,920.00**	**42,672.00**	**42,138.00**	**47,794.00**	**42,995.00**
Long-Term Debt	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,241.00	38,705.00	35,481.00	64,164.00	59,691.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,595.00	22,637.00	23,669.00	25,255.00	22,213.00
Total Liabilities	**95,945.00**	**102,383.00**	**111,775.00**	**100,141.00**	**95,664.00**	**104,148.00**	**90,756.00**	**104,014.00**	**101,288.00**	**137,213.00**	**124,899.00**
Pref. Stock, Non-Redeem.	29.00	26.00	24.00	21.00	19.00	17.00	-	-	-	-	-
Total Pref. Equity	**29.00**	**26.00**	**24.00**	**21.00**	**19.00**	**17.00**	**-**	**-**	**-**	**-**	**-**
Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Additional Paid In Capital	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00	92,278.00	93,109.00	94,083.00
Retained Earnings	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	90,392.00	103,394.00	125,656.00	118,353.00	116,725.00
Treasury Stock	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)	(113,969.00)	(114,487.00)	(114,763.00)
Comprehensive Inc. and Other	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,639.00)	(5,310.00)	(5,897.00)	(8,304.00)	(7,961.00)	(7,842.00)
Total Common Equity	**71,592.00**	**64,972.00**	**59,816.00**	**71,635.00**	**63,739.00**	**63,429.00**	**63,473.00**	**77,462.00**	**95,917.00**	**89,288.00**	**88,497.00**
Total Equity	**71,621.00**	**64,998.00**	**59,840.00**	**71,656.00**	**63,758.00**	**63,446.00**	**63,473.00**	**77,462.00**	**95,917.00**	**89,288.00**	**88,497.00**
Total Liabilities And Equity	**167,566.00**	**167,381.00**	**171,615.00**	**171,797.00**	**159,422.00**	**167,594.00**	**154,229.00**	**181,476.00**	**197,205.00**	**226,501.00**	**213,396.00**
Supplemental Items											
Total Shares Out. on Filing Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Total Shares Out. on Balance Sheet Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Book Value/Share	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74	17.03	15.77	15.56
Tangible Book Value	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,012.00)	(14,655.00)	2,846.00	915.00	(43,667.00)	(35,735.00)
Tangible Book Value/Share	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.63)	0.51	0.16	(7.73)	(6.31)
Total Debt	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,264.00	41,395.00	39,046.00	75,041.00	66,993.00
Net Debt	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,041.00	10,326.00	16,314.00	62,351.00	46,516.00
Total Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	510.00	867.00	793.00	788.00	546.00	672.00	716.00	994.00	859.00	1,007.00	976.00
Work in Progress Inventory	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,436.00	4,424.00	5,519.00	5,688.00	6,101.00
Finished Goods Inventory	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,867.00	3,641.00	2,603.00	3,495.00	3,774.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00	449.00	470.00	438.00
Full Time Employees	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00	83,000.00	88,000.00	81,000.00

Bloomberg

Company In Depth Fundamentals - Cash Flow Statement

Ticker:	PFE US EQUITY	Sort	Ascend	Currency Selection	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting Standard	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Cash Flow											
For the Fiscal Period Ending	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**	**31/12/2024**
Currency	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***
Net Income	**9,135.00**	**6,960.00**	**7,215.00**	**21,308.00**	**11,153.00**	**16,026.00**	**9,159.00**	**21,979.00**	**31,372.00**	**2,119.00**	**8,031.00**
Depreciation & Amort., Total	**5,537.00**	**5,157.00**	**5,757.00**	**6,269.00**	**6,384.00**	**5,755.00**	**4,681.00**	**5,191.00**	**5,064.00**	**6,290.00**	**7,013.00**
Other Non-Cash Adj	1,300.00	2,730.00	2,561.00	(12,169.00)	(702.00)	(3,583.00)	3,501.00	10,270.00	(8,668.00)	(3,804.00)	1,031.00
Changes in Non-Cash Capital	1,112.00	(159.00)	368.00	1,394.00	(1,008.00)	(5,610.00)	(2,938.00)	(4,860.00)	1,499.00	4,095.00	(3,331.00)
Cash from Ops.	**17,084.00**	**14,688.00**	**15,901.00**	**16,802.00**	**15,827.00**	**12,588.00**	**14,403.00**	**32,580.00**	**29,267.00**	**8,700.00**	**12,744.00**
Capital Expenditure	(1,199.00)	(1,397.00)	(1,823.00)	(1,956.00)	(2,042.00)	(2,046.00)	(2,226.00)	(2,711.00)	(3,236.00)	(3,907.00)	(2,909.00)
Sale of Property, Plant, and Equipment	-	-	-	-	-	-	-	-	-	-	-
Cash Acquisitions	(10,718.00)	(9,542.00)	(8,011.00)	(3,537.00)	(1,797.00)	(201.00)	(597.00)	(1,068.00)	(1,913.00)	(204.00)	(180.00)
Proceeds from Investment	6,145.00	6,929.00	11,254.00	3,579.00	6,244.00	232.00	723.00	649.00	641.00	1,979.00	1,570.00
Divestitures	-	-	-	-	-	-	-	-	-	-	-
Invest. in Marketable & Equity Securt.	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	118.00	1,030.00	(9,231.00)	(2,826.00)	2,120.00	(1,930.00)	(2,171.00)	(19,416.00)	(11,275.00)	(30,146.00)	4,171.00
Cash from Investing	**(5,654.00)**	**(2,980.00)**	**(7,811.00)**	**(4,740.00)**	**4,525.00**	**(3,945.00)**	**(4,271.00)**	**(22,546.00)**	**(15,783.00)**	**(32,278.00)**	**2,652.00**
Net Short Term Debt Issued/Repaid	(1,838.00)	4,309.00	(714.00)	(61.00)	(2,343.00)	10,628.00	(13,974.00)	(96.00)	(218.00)	7,683.00	(4,909.00)
Long-Term Debt Issued	4,491.00	-	10,976.00	5,274.00	4,974.00	4,942.00	5,222.00	997.00	-	30,831.00	-
Long-Term Debt Repaid	(2,110.00)	(2,990.00)	(7,689.00)	(6,154.00)	(3,566.00)	(6,806.00)	(4,003.00)	(2,004.00)	(3,298.00)	(2,569.00)	(2,250.00)
Total Debt Issued/Repaid	**543.00**	**1,319.00**	**2,573.00**	**(941.00)**	**(935.00)**	**8,764.00**	**(12,755.00)**	**(1,103.00)**	**(3,516.00)**	**35,945.00**	**(7,159.00)**
Pref. Dividends Paid	(6,609.00)	(6,940.00)	(7,317.00)	(7,659.00)	(7,978.00)	(8,043.00)	(8,440.00)	(8,729.00)	(8,983.00)	(9,247.00)	(9,512.00)
Total Dividends Paid	**(6,609.00)**	**(6,940.00)**	**(7,317.00)**	**(7,659.00)**	**(7,978.00)**	**(8,043.00)**	**(8,440.00)**	**(8,729.00)**	**(8,983.00)**	**(9,247.00)**	**(9,512.00)**
Increase in CapItal Stocks	1,002.00	1,263.00	1,019.00	862.00	1,259.00	-	-	-	-	-	-
Decrease in Capital Stocks	(5,000.00)	(6,160.00)	(5,000.00)	(5,000.00)	(12,198.00)	(8,865.00)	-	-	(2,000.00)	-	-
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	(206.00)	(891.00)	(411.00)	(559.00)	(705.00)	(374.00)	11,538.00	(43.00)	(500.00)	(672.00)	(535.00)
Cash from Financing	**(10,270.00)**	**(11,409.00)**	**(9,136.00)**	**(13,297.00)**	**(20,557.00)**	**(8,518.00)**	**(9,657.00)**	**(9,875.00)**	**(14,999.00)**	**26,026.00**	**(17,206.00)**
Net Change in Cash	**1,160.00**	**299.00**	**(1,046.00)**	**(1,235.00)**	**(205.00)**	**125.00**	**475.00**	**159.00**	**(1,515.00)**	**2,448.00**	**(1,810.00)**
Supplemental Items											
Cash Interest Paid	1,550.00	1,302.00	1,451.00	1,518.00	1,311.00	1,587.00	1,641.00	1,467.00	1,442.00	2,215.00	3,227.00
Cash Taxes Paid	2,100.00	2,383.00	2,521.00	2,489.00	3,655.00	3,664.00	3,153.00	7,427.00	7,867.00	3,147.00	3,605.00
Free Cash Flow	15,885.00	13,291.00	14,078.00	14,846.00	13,785.00	10,542.00	12,177.00	29,869.00	26,031.00	4,793.00	9,835.00
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Bloomberg

Company In Depth Fundamentals - Multiples

Ticker:	PFE US EQUITY	Sort	Ascend	
Period Type	Annuals	Consolidated	Yes	Accounting: Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples												
		31/12/2014	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**	**31/12/2024**
TEV / LTM Total Revenue	**Close**	**4.0x**	**4.4x**	**4.2x**	**4.6x**	**5.1x**	**6.4x**	**5.6x**	**4.2x**	**3.0x**	**3.8x**	**3.1x**
	Average	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x	3.6x	2.2x	3.7x
	High	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	9.0x	4.0x	3.8x	4.0x
	Low	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x	3.0x	1.6x	3.1x
TEV / LTM EBITDA	**Close**	**10.5x**	**12.7x**	**12.5x**	**12.0x**	**13.4x**	**12.5x**	**17.6x**	**13.6x**	**7.5x**	**26.8x**	**9.8x**
	Average	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x	11.5x	5.6x	26.2x
	High	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x	13.1x	26.8x	28.6x
	Low	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x	7.5x	4.0x	9.8x
TEV / LTM EBIT	**Close**	**14.9x**	**18.2x**	**18.5x**	**17.5x**	**19.5x**	**17.6x**	**28.2x**	**17.6x**	**8.7x**	**160.7x**	**15.7x**
	Average	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	31.9x	14.9x	7.0x	156.9x
	High	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.2x	45.0x	16.9x	160.7x	171.7x
	Low	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x	8.7x	4.7x	15.7x
Price / LTM EPS	**Close**	**17.5x**	**19.4x**	**15.5x**	**17.6x**	**19.3x**	**31.2x**	**19.5x**	**14.3x**	**8.3x**	**23.5x**	**11.5x**
	Average	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	22.2x	12.1x	6.0x	22.8x
	High	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	32.4x	13.8x	23.5x	25.7x
	Low	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	19.5x	14.3x	8.3x	4.2x	11.5x
Price / Book Value	**Close**	**2.7x**	**3.1x**	**3.3x**	**3.0x**	**3.9x**	**3.4x**	**3.2x**	**4.3x**	**3.0x**	**1.8x**	**1.7x**
	Average	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x	3.6x	2.2x	1.8x
	High	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x	4.1x	3.0x	2.0x
	Low	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x	3.0x	1.5x	1.6x
Price / Tangible Book Value	**Close**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**116.6x**	**314.5x**	**--**	**--**
	Average	--	--	--	--	--	--	--	116.6x	99.2x	226.6x	--
	High	--	--	--	--	--	--	--	116.6x	314.5x	314.6x	--
	Low	--	--	--	--	--	--	--	116.6x	82.4x	160.4x	--
Price / Cash Flow	**Close**	**11.6x**	**13.6x**	**12.4x**	**12.9x**	**16.2x**	**17.3x**	**14.2x**	**10.2x**	**9.8x**	18.7x	**11.8x**
	Average	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x	8.6x	7.1x	18.1x
	High	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x	9.8x	18.7x	20.4x
	Low	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x	7.2x	5.0x	11.8x
TEV / LTM FCF	**Close**	**12.4x**	**15.0x**	**14.0x**	**14.6x**	**18.6x**	**20.7x**	**16.8x**	**11.1x**	**11.0x**	**33.9x**	**15.3x**
	Average	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x	9.3x	8.1x	32.8x
	High	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	27.9x	11.0x	33.9x	37.0x
	Low	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x	7.8x	5.6x	15.3x
Dividend Yield	**Close**	**3.3**	**3.5**	**3.7**	**3.6**	**3.2**	**3.7**	**4.2**	**2.7**	**3.1**	**5.7**	**6.4**
	Average	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7	3.2	4.4	5.9
	High	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6	3.8	6.1	6.7
	Low	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5	2.8	3.1	5.3

Ticker: PFE US EQUITY | PFE US EQUITY: Ascend
Period Type: Quarters | Consolidated: Yes | Accounting: Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FQ	-9FQ	-8FQ	-7FQ	-6FQ	-5FQ	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
Ratios											
For the Fiscal Period Ending	**03/07/2022**	**02/10/2022**	**31/12/2022**	**02/04/2023**	**02/07/2023**	**01/10/2023**	**31/12/2023**	**31/03/2024**	**30/06/2024**	**29/09/2024**	**31/12/2024**
Profitability											
Return on Assets	16.1%	15.9%	16.6%	15.3%	10.3%	5.1%	1.0%	-0.1%	-1.2%	2.0%	3.7%
Return on Capital	25.7%	25.2%	25.6%	23.6%	15.7%	8.2%	2.6%	1.2%	-0.1%	4.2%	6.6%
Return on Equity	37.3%	35.4%	36.3%	31.7%	23.1%	11.1%	2.3%	-0.3%	-2.8%	4.5%	9.1%
Margin Analysis											
Gross Margin	68.8%	73.2%	60.3%	73.6%	75.1%	30.0%	48.1%	77.3%	75.2%	70.3%	66.7%
SG&A Margin	10.5%	14.3%	18.2%	18.1%	26.3%	24.2%	30.7%	23.2%	27.6%	18.2%	24.1%
EBITDA Margin	35.3%	38.4%	39.9%	40.2%	35.5%	22.9%	12.3%	9.2%	7.3%	21.0%	30.5%
EBIT Margin	30.4%	33.6%	34.8%	34.4%	28.1%	14.0%	1.7%	-2.6%	-4.7%	9.6%	19.5%
Earnings from Cont. Ops Margin	44.0%	39.5%	18.1%	35.4%	16.9%	-25.9%	-29.4%	27.6%	7.6%	28.0%	13.2%
Net Income Margin	35.7%	38.0%	20.6%	30.0%	17.9%	-18.0%	-23.1%	20.9%	0.3%	25.2%	2.3%
Normalized Net Income Margin	38.4%	42.1%	23.7%	33.3%	21.8%	-12.7%	-1.3%	24.0%	16.7%	28.6%	12.8%
Free Cash Flow Margin	26.7%	40.2%	14.9%	0.4%	-16.3%	20.0%	28.8%	2.6%	-18.2%	34.3%	32.7%
Asset Turnover											
Total Asset Turnover	0.6x	0.5x	0.5x	0.5x	0.4x	0.3x	0.3x	0.3x	0.3x	0.3x	0.3x
Fixed Asset Turnover	6.9x	6.7x	5.4x	5.8x	4.8x	4.1x	2.9x	3.1x	3.1x	3.3x	3.0x
Accounts Receivable Turnover	7.9x	7.1x	8.9x	7.3x	6.2x	5.1x	5.4x	4.8x	5.2x	4.7x	5.6x
Inventory Turnover	3.9x	3.8x	3.8x	3.0x	2.3x	2.7x	2.6x	2.3x	2.2x	1.8x	1.7x
Short Term Liquidity											
Current Ratio	1.4x	1.6x	1.2x	1.4x	2.1x	2.4x	0.9x	1.0x	0.9x	1.0x	1.2x
Quick Ratio	1.0x	1.2x	0.8x	0.9x	1.6x	1.8x	0.5x	0.6x	0.4x	0.6x	0.7x
Cash from Ops. To Curr Liab.	0.7x	0.8x	0.5x	0.5x	1.3x	1.4x	0.3x	0.3x	0.2x	0.2x	0.5x
Avg. Days Sales Out.	46.3x	51.0x	40.8x	49.9x	58.9x	71.6x	68.1x	76.1x	70.3x	76.9x	65.1x
Avg. Days Inventory Out.	92.2x	96.0x	95.9x	121.5x	158.6x	132.7x	140.2x	158.6x	168.4x	204.6x	215.7x
Avg. Days Payable Out.	48.2x	56.5x	66.0x	73.5x	94.4x	76.2x	94.3x	86.0x	82.6x	92.2x	122.0x
Avg. Cash Conversion Cycle	90.3x	90.4x	70.7x	97.9x	123.1x	128.2x	114.0x	148.8x	156.2x	189.3x	158.8x
Long Term Solvency											
Total Debt/Equity	46.1%	39.5%	40.7%	35.5%	65.8%	65.4%	84.0%	75.1%	78.9%	73.1%	75.7%
Total Debt/Capital	31.5%	28.3%	28.9%	26.2%	39.7%	39.5%	45.7%	42.9%	44.1%	42.2%	43.1%
LT Debt/Equity	39.3%	35.2%	37.1%	31.4%	62.0%	63.0%	72.1%	66.4%	65.6%	62.9%	67.7%
LT Debt/Capital	26.8%	25.2%	26.3%	23.1%	37.3%	38.0%	39.0%	37.8%	36.5%	36.2%	38.4%
Total Liabilities/Total Assets	30.9%	29.8%	30.0%	29.6%	39.2%	40.3%	39.5%	39.8%	39.0%	38.1%	38.4%
EBIT / Interest Exp.	41.70x	28.76x	14.01x	20.58x	4.32x	-4.93x	-6.22x	5.19x	1.29x	6.33x	3.18x
EBITDA / Interest Exp.	45.71x	32.56x	18.86x	25.26x	7.42x	-2.69x	-3.80x	7.39x	3.51x	8.56x	5.60x
(EBITDA-CAPEX) / Interest Exp.	43.15x	29.86x	15.66x	21.68x	5.62x	-3.85x	-5.31x	6.50x	2.70x	7.73x	4.36x
Total Debt/EBITDA	1.13x	0.96x	0.98x	0.96x	2.35x	4.02x	10.27x	13.60x	17.01x	5.34x	3.45x
Net Debt/EBITDA	0.20x	0.01x	0.41x	0.43x	0.74x	1.23x	8.53x	11.26x	15.27x	4.56x	2.39x
Altman Z Score	4.99	4.95	5.63	5.37	4.0	3.63	3.1	3.24	3.09	3.52	3.82
Growth Over Prior Year											
Total Revenue	46.8%	(5.8%)	1.9%	(28.0%)	(53.1%)	(41.5%)	(40.0%)	(19.5%)	2.1%	33.8%	21.9%
Gross Profit	60.4%	17.5%	3.8%	(13.2%)	(48.8%)	(76.1%)	(52.1%)	(15.4%)	2.2%	213.9%	69.1%
EBITDA	93.7%	35.2%	38.3%	(24.1%)	(71.9%)	(118.5%)	(144.3%)	(27.3%)	(27.4%)	(458.8%)	(258.1%)
EBITA	99.9%	37.2%	39.7%	(25.3%)	(74.1%)	(123.1%)	(154.8%)	(29.3%)	(44.3%)	(378.5%)	(222.7%)
EBIT	118.0%	45.5%	46.6%	(30.4%)	(82.0%)	(138.4%)	(197.8%)	(37.3%)	(54.3%)	(244.5%)	(154.8%)
Earnings from Cont. Ops.	69.5%	5.8%	39.8%	(29.5%)	(76.3%)	(127.6%)	(166.7%)	(43.7%)	(98.7%)	(287.6%)	(112.3%)
Net Income	78.1%	5.7%	47.2%	(29.5%)	(76.5%)	(127.7%)	(167.4%)	(43.8%)	(98.2%)	(287.4%)	(112.2%)
Normalized Net Income	91.6%	53.5%	(3.3%)	(31.1%)	(73.4%)	(117.6%)	(103.2%)	(42.0%)	(21.7%)	(400.9%)	(1,316.7%)
Diluted EPS before Extra	69.6%	5.6%	40.3%	(29.2%)	(76.3%)	(127.8%)	(167.8%)	(43.3%)	(97.6%)	(288.1%)	(111.9%)
Accounts Receivable	43.1%	35.1%	(4.6%)	(7.0%)	(32.5%)	(31.0%)	2.1%	(10.7%)	11.4%	30.4%	2.6%
Inventory	16.8%	10.1%	(0.9%)	(4.4%)	(1.4%)	7.3%	13.5%	14.2%	11.0%	14.9%	6.5%
Net PP&E	7.2%	7.0%	8.8%	12.9%	14.7%	15.7%	13.4%	10.3%	8.4%	3.8%	(5.4%)
Total Assets	14.9%	9.0%	8.7%	6.4%	12.7%	10.1%	14.9%	13.0%	(1.8%)	2.1%	(5.8%)
Tangible Book Value	(214.4%)	(14,559.9%)	(67.8%)	209.5%	(27.5%)	(65.7%)	(4,847.0%)	(629.7%)	(792.3%)	(797.3%)	(18.5%)
Common Equity	24.5%	22.4%	23.9%	22.5%	13.5%	4.6%	(6.9%)	(8.6%)	(11.4%)	(4.8%)	(0.9%)
Cash from Ops.	(27.7%)	(8.3%)	(21.8%)	(81.5%)	(114.8%)	(65.2%)	13.4%	(10.1%)	47.4%	94.3%	28.3%
Capital Expenditures	39.9%	36.1%	0.8%	77.1%	21.7%	(3.7%)	4.3%	(38.2%)	(30.3%)	(19.6%)	(12.2%)
Levered Free Cash Flow	(31.1%)	(10.9%)	(26.4%)	(98.8%)	(128.6%)	(70.9%)	15.9%	428.8%	13.9%	129.1%	38.3%
Unlevered Free Cash Flow	(39.7%)	(14.7%)	(49.6%)	(161.1%)	(185.7%)	(95.2%)	36.7%	(10.9%)	8.1%	1,009.3%	82.0%
Dividend per Share	0.0%	2.6%	2.6%	2.5%	2.5%	2.5%	2.5%	2.4%	2.4%	2.4%	2.4%
CAGR Over Two Years											
Total Revenue	67.7%	48.4%	44.5%	12.8%	(17.0%)	(25.8%)	(21.8%)	(23.9%)	(30.8%)	(11.6%)	(14.5%)
Gross Profit	54.1%	41.6%	29.2%	14.6%	(9.4%)	(47.0%)	(29.5%)	(14.4%)	(27.7%)	(13.4%)	(10.0%)
EBITDA	102.4%	62.9%	86.2%	16.7%	(26.2%)	--	--	(25.8%)	(54.8%)	(18.6%)	(16.3%)
EBITA	110.6%	68.1%	95.9%	17.4%	(28.0%)	--	--	(27.3%)	(62.0%)	(19.9%)	(18.0%)
EBIT	142.8%	91.1%	158.5%	18.1%	(37.4%)	--	--	(34.0%)	(71.3%)	(25.5%)	(26.8%)
Earnings from Cont. Ops.	94.8%	207.0%	180.9%	6.6%	(36.6%)	--	--	(37.0%)	(94.4%)	(28.0%)	(71.3%)
Net Income	68.5%	142.1%	142.8%	6.6%	(35.3%)	--	--	(37.1%)	(93.6%)	(28.0%)	(71.4%)
Normalized Net Income	95.0%	104.7%	195.5%	14.5%	(28.6%)	--	--	(36.8%)	(54.4%)	(27.1%)	(37.2%)
Diluted EPS before Extra	93.9%	207.2%	181.2%	6.2%	(36.6%)	--	--	(36.6%)	(92.4%)	(27.7%)	(71.6%)
Accounts Receivable	28.9%	26.7%	17.6%	11.7%	(1.7%)	(3.5%)	(1.3%)	(8.8%)	(13.3%)	(5.2%)	2.3%
Inventory	10.5%	1.2%	5.8%	6.0%	7.3%	8.7%	6.1%	4.5%	4.6%	11.0%	9.9%
Net PP&E	3.9%	3.5%	12.9%	10.3%	10.9%	11.2%	11.1%	11.6%	11.5%	9.6%	3.6%
Total Assets	4.8%	4.5%	13.1%	11.0%	13.8%	9.5%	11.7%	9.7%	5.2%	6.0%	4.0%
Tangible Book Value	--	--	--	--	--	--	--	--	--	--	--
Common Equity	16.4%	19.1%	23.0%	21.3%	18.9%	13.2%	7.4%	5.8%	0.3%	(0.2%)	(4.0%)
Cash from Ops.	51.6%	118.0%	(9.4%)	(48.3%)	--	(43.5%)	(5.9%)	(59.2%)	--	(17.8%)	20.6%
Capital Expenditures	28.2%	22.4%	12.9%	43.4%	30.5%	14.5%	2.5%	4.6%	(7.9%)	(12.0%)	(4.3%)
Levered Free Cash Flow	54.8%	143.9%	(13.5%)	(86.5%)	--	(49.1%)	(7.7%)	(74.4%)	--	(18.3%)	26.6%
Unlevered Free Cash Flow	129.0%	--	(29.0%)	--	--	(79.7%)	(17.0%)	--	--	(26.7%)	57.7%
Dividend per Share	2.6%	2.6%	1.3%	2.5%	1.2%	2.5%	2.5%	2.5%	2.5%	2.5%	2.5%
CAGR Over Three Years											
Total Revenue	27.9%	21.3%	32.5%	22.4%	9.7%	8.8%	7.8%	0.8%	(11.1%)	(9.7%)	(9.3%)
Gross Profit	21.3%	18.0%	20.5%	18.6%	6.7%	(21.7%)	(7.2%)	3.5%	(5.7%)	(4.1%)	(5.6%)
EBITDA	31.6%	(7.3%)	48.7%	24.1%	4.8%	(178.9%)	(215.4%)	(0.3%)	(26.6%)	(3.6%)	(1.0%)
EBITA	33.8%	(7.3%)	53.5%	25.4%	4.7%	(186.7%)	(228.1%)	(0.8%)	(33.9%)	(4.1%)	(2.1%)
EBIT	42.0%	(6.8%)	102.3%	29.2%	1.9%	(211.9%)	(287.0%)	(4.4%)	(43.7%)	(6.9%)	(7.8%)
Earnings from Cont. Ops.	25.0%	4.0%	(268.6%)	30.8%	(3.5%)	(237.6%)	(273.9%)	(13.8%)	(82.5%)	(18.1%)	(51.4%)
Net Income	25.2%	3.9%	(345.6%)	18.2%	(12.6%)	(217.5%)	(258.4%)	(13.9%)	(80.5%)	(18.2%)	(50.6%)
Normalized Net Income	41.9%	42.3%	59.2%	30.1%	0.4%	(190.4%)	(165.2%)	(8.2%)	(26.4%)	(6.6%)	(27.5%)
Diluted EPS before Extra	24.8%	3.5%	(366.1%)	30.1%	(3.8%)	(237.0%)	(275.0%)	(13.8%)	(78.6%)	(17.9%)	(51.7%)
Accounts Receivable	15.7%	19.4%	17.4%	7.6%	3.9%	3.5%	12.2%	3.7%	2.5%	6.7%	(0.0%)
Inventory	8.3%	5.0%	8.3%	4.2%	6.4%	3.2%	8.3%	8.6%	8.6%	10.7%	6.2%
Net PP&E	1.0%	1.0%	10.6%	6.7%	7.4%	7.4%	13.1%	10.3%	10.0%	8.7%	5.3%
Total Assets	7.7%	4.7%	5.6%	5.6%	7.4%	6.3%	13.7%	11.7%	8.4%	7.0%	5.5%
Tangible Book Value	(167.4%)	(176.9%)	(136.2%)	(164.1%)	(159.0%)	(158.4%)	43.2%	62.6%	79.1%	601.6%	(331.8%)
Common Equity	13.6%	12.5%	14.0%	15.8%	15.5%	14.1%	12.1%	10.4%	7.8%	6.8%	4.5%
Cash from Ops.	46.3%	30.1%	7.0%	(27.1%)	(169.8%)	18.3%	(2.3%)	(37.8%)	(154.0%)	(14.7%)	4.4%
Capital Expenditures	16.2%	14.2%	20.8%	26.4%	26.0%	13.0%	10.0%	8.3%	5.0%	1.2%	(2.6%)
Levered Free Cash Flow	51.5%	32.1%	4.2%	(69.9%)	(188.1%)	20.1%	(4.6%)	(54.1%)	(160.8%)	(15.0%)	5.7%
Unlevered Free Cash Flow	241.4%	52.2%	4.4%	(256.8%)	(265.0%)	(182.9%)	(11.7%)	(203.1%)	(182.4%)	(22.9%)	7.8%
Dividend per Share	3.6%	3.6%	3.6%	2.6%	2.6%	2.6%	1.7%	2.5%	1.6%	2.5%	2.5%
CAGR Over Five Years											
Total Revenue	16.6%	11.4%	12.1%	7.5%	(0.7%)	(0.1%)	0.8%	2.6%	0.0%	6.9%	11.2%
Gross Profit	13.3%	8.9%	7.0%	5.6%	(1.5%)	(17.9%)	(8.5%)	1.5%	(1.4%)	4.3%	7.2%
EBITDA	20.3%	14.1%	8.8%	7.8%	(7.4%)	(181.0%)	(192.1%)	(0.7%)	(14.2%)	(12.0%)	18.2%
EBITA	21.4%	15.1%	9.6%	8.3%	(8.1%)	(185.2%)	(196.7%)	(0.7%)	(19.2%)	(12.5%)	19.4%
EBIT	26.7%	19.5%	13.7%	10.6%	(11.2%)	(198.2%)	(213.1%)	(1.5%)	(25.1%)	(14.8%)	34.7%
Earnings from Cont. Ops.	26.3%	24.8%	(16.5%)	9.2%	(9.6%)	(189.7%)	54.2%	(4.3%)	(63.9%)	(10.2%)	(183.0%)
Net Income	26.4%	24.8%	(16.5%)	9.3%	(9.7%)	(189.6%)	53.6%	(4.3%)	(61.8%)	(10.3%)	(204.0%)
Normalized Net Income	25.1%	23.8%	13.9%	11.3%	(4.5%)	(185.1%)	(33.4%)	(3.0%)	(9.8%)	8.8%	9.8%
Diluted EPS before Extra	27.7%	26.3%	(15.5%)	10.5%	(8.8%)	(190.5%)	53.2%	(4.2%)	(59.3%)	(10.3%)	(181.9%)
Accounts Receivable	9.8%	10.0%	5.9%	5.4%	0.7%	2.0%	6.9%	2.7%	3.1%	8.9%	11.1%
Inventory	6.6%	3.7%	3.5%	3.2%	5.0%	4.5%	6.3%	6.3%	6.8%	7.3%	9.0%
Net PP&E	2.6%	2.7%	6.8%	4.1%	4.7%	4.9%	10.3%	5.0%	5.1%	4.3%	7.7%
Total Assets	3.0%	2.6%	2.8%	3.5%	5.9%	5.1%	7.3%	7.3%	6.7%	5.2%	5.0%
Tangible Book Value	(171.2%)	(181.3%)	(149.3%)	(174.5%)	(171.9%)	(170.9%)	11.9%	6.3%	9.0%	1.7%	12.9%
Common Equity	8.4%	8.8%	6.1%	7.6%	7.3%	6.3%	7.0%	9.4%	8.1%	7.2%	6.9%
Cash from Ops.	20.3%	15.2%	(8.2%)	(9.4%)	(179.3%)	(8.1%)	2.0%	(8.5%)	(192.6%)	8.3%	12.3%
Capital Expenditures	10.9%	13.3%	7.4%	24.2%	16.6%	8.2%	8.8%	8.9%	5.9%	2.9%	10.1%
Levered Free Cash Flow	21.6%	15.4%	(10.7%)	(46.0%)	(190.9%)	(10.9%)	0.7%	(20.8%)	(202.5%)	9.0%	12.6%
Unlevered Free Cash Flow	42.5%	21.9%	(21.0%)	38.7%	(225.3%)	(34.3%)	(2.1%)	19.7%	(305.8%)	13.7%	23.1%
Dividend per Share	4.6%	4.6%	4.6%	3.8%	3.8%	3.8%	3.8%	3.1%	3.1%	3.1%	3.1%

Bloomberg

Company In Depth Fundamentals - Capital Structure Summary

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting / Change / USD
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
WACC					
For the Fiscal Period Ending	31/12/2023	31/03/2024	30/06/2024	29/09/2024	31/12/2024
	%	%	%	%	%
Equity					
Cost of Equity	8.9%	7.9%	7.8%	7.1%	7.2%
Weight of Equity	68.4%	69.3%	69.5%	70.9%	69.2%
+ Debt					
Cost of Debt	5.1%	5.0%	5.7%	4.5%	5.8%
Weight of Debt	31.6%	30.7%	30.5%	29.1%	30.8%
+ Preferred Equity					
Cost of Pref Equity	--	--	--	--	--
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	**7.7%**	**7.0%**	**7.1%**	**6.3%**	**6.8%**

Capital Structure										
For the Fiscal Period Ending	31/12/2023		31/03/2024		30/06/2024		29/09/2024		31/12/2024	
Currency	*USD*		*USD*		*USD*		*USD*		*USD*	
	Millions	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*
Hist Market Cap										
ST Borrowings	10,877.0	*4.6%*	8,232.0	*3.6%*	11,944.0	*5.2%*	9,699.0	*4.2%*	7,302.0	*3.4%*
LT Borrowings	64,164.0	*27.0%*	61,307.0	*27.0%*	57,506.0	*25.2%*	58,002.0	*24.9%*	59,691.0	*27.5%*
Pref Equity	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*
Total Capital	**237,589.3**	***100.0%***	**226,798.3**	***100.0%***	**228,012.7**	***100.0%***	**232,524.9**	***100.0%***	**217,338.5**	***100.0%***

Debt Summary Data										
For the Fiscal Period Ending	31/12/2023		31/03/2024		30/06/2024		29/09/2024		31/12/2024	
Currency	*USD*		*USD*		*USD*		*USD*		*USD*	
	Millions	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*	*Millions*	*% of Total*
Total Commercial Paper	0.0	*0.0%*	--	--	--	--	0.0	*0.0%*	0.0	*0.0%*
Total Revolving Credit	15,031.0	*20.0%*	15,000.0	*21.6%*	15,000.0	*21.6%*	15,000.0	*22.2%*	15,033.0	*22.4%*
Total Capital Leases	--	--	--	--	--	--	--	--	--	--
General/Other Borrowings				*78.4%*	54,450.0	*78.4%*		*77.8%*	51,960.0	*77.6%*
Total Principal Due	**75,041.0**	***100.0%***	**69,539.0**	***100.0%***	**69,450.0**	***100.0%***	**67,701.0**	***100.0%***	**66,993.0**	***100.0%***
Total Debt Outstanding	**75,041.0**		**69,539.0**		**69,450.0**		**67,701.0**		**66,993.0**	
Additional Totals										
Total Cash & ST Investments	12,690.0	*16.9%*	11,928.0	*17.2%*	7,100.0	*10.2%*	9,952.0	*14.7%*	20,477.0	*30.6%*
Net Debt	62,351.0	*83.1%*	57,611.0	*82.8%*	62,350.0	*89.8%*	57,749.0	*85.3%*	46,516.0	*69.4%*
Total Short-Term Borrowings	10,877.0	*14.5%*	8,232.0	*11.8%*	11,944.0	*17.2%*	9,699.0	*14.3%*	7,302.0	*10.9%*
Curr. Port. of LT Debt/Cap. Leases	10,877.0	*14.5%*	8,232.0	*11.8%*	11,944.0	*17.2%*	9,699.0	*14.3%*	7,302.0	*10.9%*
Long-Term Debt (Incl. Cap. Leases)	64,164.0	*85.5%*	61,307.0	*88.2%*	57,506.0	*82.8%*	58,002.0	*85.7%*	59,691.0	*89.1%*
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--
Credit Ratios										
Net Debt/EBITDA	8.5x		11.3x		15.3x		4.6x		2.4x	
Total Debt/EBITDA	10.3x		13.6x		17.0x		5.3x		3.4x	
Operating Income/Total Debt	-0.1x		0.1x		0.0x		0.1x		0.0x	
LTM FCF/Total Debt	0.1x		0.1x		0.1x		0.1x		0.1x	
LTM CFO/Total Debt	0.1x		0.1x		0.1x		0.2x		0.2x	
EBIT/Interest Expense	-6.2x		5.2x		1.3x		6.3x		3.2x	
EBIT/Total Interest Expense	-6.2x		5.2x		1.3x		6.3x		3.2x	
Degree of Financial Leverage	--		1.2x		4.5x		1.2x		1.5x	
(EBITDA-CAPEX)/Interest Expense	-5.3x		6.5x		2.7x		7.7x		4.4x	
EBITDA/Total Interest Expense	-3.8x		7.4x		3.5x		8.6x		5.6x	
Debt Schedule										
Debt Schedule In Yr 1	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 2	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 3	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 4	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule Beyond Yr 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Total Debt	**71,888.0**	***100.0%***	**69,539.0**	***100.0%***	**69,450.0**	***100.0%***	**67,701.0**	***100.0%***	**64,351.0**	***100.0%***
Capital Lease Schedule										
Capital Leases - Year 1	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Future Value of Capital Leases	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
Present Value of ST Capital Leases	--		--		--		--		--	
Present Value of LT Capital Leases	--		--		--		--		--	
Operating Leases (Rental Expense) Schedule										
Rental Expense - Year 1	639.0	*16.7%*	--	--	--	--	--	--	443.0	*13.9%*
Rental Expense - Year 2	474.0	*12.4%*	--	--	--	--	--	--	406.0	*12.7%*
Rental Expense - Year 3	387.0	*10.1%*	--	--	--	--	--	--	361.0	*11.3%*
Rental Expense - Year 4	319.0	*8.3%*	--	--	--	--	--	--	281.0	*8.8%*
Rental Expense - Year 5	262.0	*6.9%*	--	--	--	--	--	--	239.0	*7.5%*
Rental Expense - Years 2 - 3	861.0	*22.5%*	--	--	--	--	--	--	767.0	*24.0%*
Rental Expense - Years 4 - 5	581.0	*15.2%*	--	--	--	--	--	--	520.0	*16.3%*
Rental Expense - Years 2 - 5	1,442.0	*37.7%*	--	--	--	--	--	--	1,287.0	*40.2%*
Rental Expense Beyond Year 5	1,743.0	*45.6%*	--	--	--	--	--	--	1,468.0	*45.9%*
Total Sublease Income	--	--	--	--	--	--	--	--	--	--
Future Min Oper Lease Obligations	**3,824.0**	***100.0%***	**--**	**--**	**--**	**--**	**--**	**--**	**3,198.0**	***100.0%***
Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	--	--	--	--	--	--	--	--
Contractual Obligations- Years 2-3	--	--	--	--	--	--	--	--	--	--
Contractual Obligations- Years 4-5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Contractual Obligations	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
Purchase Obligations	**5,200.0**		**--**		**--**		**--**		**4,100.0**	
Interest Rate Data										
W/Avg. Interest Rate - Long-term Debt	--		--		--		--		--	

Bloomberg

Company In Depth Fundamentals - Segments

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE							31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Revenue by Product For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Revenue	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,651.00**	**81,288.00**	**100,330.00**	**59,554.00**	**63,627.00**
Biopharma	25,600.00	26,758.00	29,197.00	31,422.00	37,558.00	38,344.00	41,651.00	79,557.00	98,989.00	58,238.00	62,399.00
Business Innovation	24,005.00	22,093.00	23,627.00	21,124.00	12,484.00	2,828.00	-	1,731.00	1,342.00	1,316.00	1,228.00
Pfizer Ignite	-	-	-	-	3,605.00	-	-	-	-	-	-
Pfizer Centreone	-	-	-	-	-	-	-	-	-	-	-
Reconciling Items	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Revenue	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,651.00**	**81,288.00**	**100,330.00**	**59,554.00**	**63,627.00**
United States	19,073.00	21,704.00	26,369.00	26,026.00	25,329.00	20,593.00	21,455.00	29,746.00	42,473.00	-	-
International	11,719.00	11,136.00	10,420.00	11,400.00	12,651.00	8,828.00	8,370.00	20,702.00	21,982.00	-	-
	11,499.00	9,713.00	9,304.00	8,510.00	9,116.00	7,729.00	7,788.00	18,334.00	20,097.00	-	-
	7,314.00	6,298.00	6,731.00	6,610.00	6,551.00	4,022.00	4,038.00	12,505.00	15,778.00	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Bloomberg

Company In Depth Fundamentals - Pension

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00	116.00	85.00	87.00
Interest Cost	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00	691.00	876.00	865.00
Expected Return on Plan Assets	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,329.00)	(1,379.00)	(1,158.00)	(1,082.00)	(1,154.00)
Pension Expense (Income)	402.00	1,203.00	696.00	695.00	(2.00)	331.00	809.00	(2,011.00)	(129.00)	(423.00)	237.00
Other Postretirement Cost											
Service Cost	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00	29.00	12.00	14.00
Interest Cost	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00	27.00	21.00	23.00
Expected Return on Plan Assets	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(39.60)	(39.00)	(47.00)	(44.00)	(51.00)
Other Postretirement Benefits Expense (I	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(282.00)	(372.00)	(578.00)	(90.00)	18.00
Pension Funded Status											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Actual Return (Loss) on Plan Assets	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	--	--	--	--	--
Employer Contribution	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	197.00	451.00	156.00	154.00	267.00
Benefits Paid	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)	(816.00)	(791.00)	(844.00)
Projected Benefit Obligation	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00	18,917.00	18,048.00	17,144.00
Over(Under) Funded Pension	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)	(1,181.00)	(561.00)	(500.00)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99	93.76	96.89	97.08
Other Postretirement Funded Status											
Fair Value of Plan Assets	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00	647.00	636.00	736.00
Actual Return (Loss) on Plan Assets	45.00	(3.00)	44.00	39.00	(22.00)	50.00	--	--	--	--	--
Employer Contribution	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00	65.00	--	-
Benefits Paid	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	--	--	--	--	--
Projected Benefit Obligation	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00	410.00	450.00	486.00
Over(Under) Funded Post Ret Benefits	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)	237.00	186.00	250.00
Other Post-Retirement Funding Ratio	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68	157.80	141.33	151.44
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.90	5.40	5.40	5.40
Rate of Compensation Increase	2.76	2.80	2.74	2.80	2.80	-	-	--	-	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90	5.50	5.40	5.50
Health Care Cost Trend Projected(next y	7.00	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Asset Category - Equities %	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00	30.00	30.00	12.87
Asset Category - Debt %	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00	60.00	50.00	50.03
Asset Category - Real Estate %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Company Stock %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Cash %	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00	5.00	5.00	5.06
Asset Category - Other %	18.41	21.20	19.70	18.30	18.20	17.00	16.60	12.50	5.00	15.00	32.03
Expected Pension Payments											
Year 1	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00	1,346.00	1,381.00	1,255.00
Year 2	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00	1,312.00	1,268.00	1,224.00
Year 3	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00	1,292.00	1,265.00	1,228.00
Year 4	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00	1,280.00	1,259.00	1,210.00
Year 5	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00	1,277.00	1,244.00	1,207.00
Beyond Year 5	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00	6,287.00	6,077.00	5,827.00
Expected Postretirement Benefits											
Year 1	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00	42.00	43.00	44.00
Year 2	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00	43.00	45.00	47.00
Year 3	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00	44.00	46.00	49.00
Year 4	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00	44.00	47.00	50.00
Year 5	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00	43.00	47.00	50.00
Beyond Year 5	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00	192.00	218.00	245.00

Bloomberg

Company In Depth Fundamentals - Supplemental

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Supplemental											
For the Fiscal Period Ending	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**	**31/12/2024**
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Options Activity											
Options Granted During Period	44.60	46.13	1.37	1.38	1.37	1.18	1.76	0.78	0.43	0.64	1.37
Options Outstanding End Of Period	249.11	232.55	186.68	150.76	103.79	88.60	75.40	44.87	35.28	28.45	19.62
Options Exercisable End of Period	122.62	109.56	105.86	108.75	100.08	85.37	71.73	41.58	32.46	26.67	17.45
Price											
Weighted Average Fair Value per Option	-	-	-	-	-	-	-	-	-	-	-
Avg Exercise Price (Options Outstanding)	24.05	26.41	26.86	27.27	27.69	28.39	28.31	30.20	31.47	32.66	33.24
Avg Exercise Price (Options Exercisable)	21.19	-	-	24.49	27.47	28.04	27.97	29.81	31.18	32.19	33.12
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	3.72	1.89	1.55	2.23	2.85	2.55	1.25	1.27	1.93	4.03	4.32
Stock Opt Valuation - Expected Life (Yrs)	6.50	6.75	6.75	6.75	6.75	5.13	5.12	6.75	6.50	6.50	6.50
Stock Opt Valuation - Expected Volatil (%)	19.76	18.34	21.64	18.39	20.02	18.34	20.97	26.54	29.21	23.23	26.56
Stock Opt Valuation - Dividend Yield (%)	3.18	3.19	3.85	3.69	3.73	3.27	4.36	4.51	3.42	3.80	6.06
Stock Expense											
Expense For Stock-Based Compensation	586.00	669.00	691.00	840.00	949.00	718.00	780.00	1,200.00	872.00	525.00	877.00
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-